Download our flyer here

Register here

Announcing MAP’s conference 2020

Patient Access 2020: Innovation for UK market access

Tuesday 22nd September 2020 – Royal College of Physicians, London

A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.

Our conference has been designed around three core market access areas. Each with a specific mission to bring you the latest insights and information for accelerating patient access.

Developments in strategy and HTA

The importance of patient engagement throughout the HTA process

Using patient registries in HTAs

Appraisal process of medical devices compared with drugs

Health economic modelling of digital apps

Access to Orphan Medicines: Developing policies for the future

Innovation tools

Approaches to utilising Real World Evidence (RWE)

Using analytics and big data to gain competitive advantage in Market Access

Collaborative working and horizon scanning

Harnessing digital systems and technology to find new levels of patient value

Pricing and policy

VPAS – what you need to know

Updates on The Commercial Framework

Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs

The NHS Long Term Plan and what this actually means for pharma companies

Confirmed Speakers

  • Lindsay Weaver, CEO, Metabolic Support UK – on the importance of patient engagement throughout the HTA process
  • David Gillen, Vice President international Medical Affairs, Vertex – on using patient registries in HTAs
  • Sheela Uppadhyaya, Associate Director Technology Appraisals and Highly Specialised Technologies, NICE – on Orphan medicines, policy and patient engagement
  • Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners – on approaches to utilising Real World Evidence (RWE)
  • David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI) – on the Voluntary Scheme; what you need to know
  • Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group – on Harnessing digital systems and technology to find new levels of patient value

Who should attend?

This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.

The job functions that will benefit most include:

  • Heads of Market Access
  • Country Managers
  • Health Economists
  • Commercial Directors
  • Marketing Directors
  • Managing Directors
  • Chief Executives
  • Medical Directors
  • Policy Officers/Executives
  • Policy Advisors


Previous Conferences:

MAP Conference 2018

MAP Conference 2017

MAP Conference 2016

MAP Conference 2015